BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Hypertension clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for hypertension: 364 (213 sponsors; 76 newly posted in the last 180 days, 20 stopped in the last 180 days; 40 new-entrant sponsors). Momentum score 16.3, rank 39 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 40, Phase 2 66, Phase 3 65, Phase 4 13, N/A 179.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Insmed Incorporated INSM4P3 401
AstraZeneca AZN6P3 3, NA 2, P2 112
Liquidia Technologies, Inc. LQDA5P3 3, P4 1, NA 111
Actelion4P3 3, P2 101
Eli Lilly and Company LLY4P3 3, P2 111
Tenax Therapeutics, Inc. TENX3P3 300
Merck Sharp & Dohme LLC MRK9P2 5, P4 2, P3 240
United Therapeutics UTHR6P3 2, P2 1, NA 2, P4 122
SpyGlass Pharma, Inc. SGP5P1 1, NA 1, P3 2, P2 111
Ablative Solutions, Inc.2P3 200
Inhibikase Therapeutics IKT2P3 210
Shandong Suncadia Medicine Co., Ltd.2P3 210
Boryung Pharmaceutical Co., Ltd9P1 4, NA 3, P2 1, P3 112
Glaukos Corporation GKOS7P4 2, P2 1, NA 3, P3 112
Addpharma Inc.4P1 3, P3 100
AOP Orphan Pharmaceuticals AG4NA 2, P4 1, P3 110
Innovent Biologics (Suzhou) Co. Ltd.4P1 2, P2 1, P3 111
AbbVie ABBV3P4 1, P2 1, P3 100
Pulmovant, Inc.3P2 2, P3 111
Alnylam Pharmaceuticals ALNY2P2 1, P3 100
Bayer2NA 1, P3 100
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. new entrant2P2 1, P3 121
Hanmi Pharmaceutical Company Limited HAFC new entrant2P3 1, NA 120
Huons Co., Ltd.2P1 1, P3 111
Pulnovo Medical (Wuxi) Co., Ltd.2P3 1, NA 100

New-entrant sponsors: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Hanmi Pharmaceutical Company Limited.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3United Therapeutics UTHRNCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseasenrolling by invitation1000
2026-12 est.P3Boryung Pharmaceutical Co., LtdNCT06220773 A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapyEssential Hypertension; Type 2 Diabetes Mellitusrecruiting276
2026-12 est.P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07297797 Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate HypertensionMild to Moderate Hypertensionactive not recruiting238
2026-12 est.P2Qilu Pharmaceutical Co., Ltd.NCT07489612 QLS1410 in Participants With Uncontrolled HypertensionHypertension (HTN)enrolling by invitation260
2026-12 est.P2Kardigan, Inc. KARDNCT07511361 Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionHypertension; Acute Severe Hypertension; Hypertensive Emergency; Hypertensive Urgencyrecruiting140
2026-12-10 est.P2AstraZeneca AZNNCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic KiChronic Kidney Disease and Hypertensionactive not recruiting222
2027-01 est.P1/P2EyeD PharmaNCT07036510 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract SurgeryGlaucoma; Ocular Hypertensionrecruiting42
2027-01-31 est.P3ActelionNCT05179876 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionHypertension, Pulmonaryrecruiting280
2027-01-31 est.P2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07940075 SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .Mild to Moderate Primary Hypertensionrecruiting360
2027-02-01 est.P2Boryung Pharmaceutical Co., LtdNCT07373613 A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential HypertensionEssential Hypertensionnot yet recruiting330

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-12-22PDUFA date (company-disclosed)pendingMineralys Therapeutics, Inc. MLYSlorundrostatPDUFA December 22, 2026 - Mineralys Therapeutics, Inc. (lorundrostat)

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-15 est.P2PolyActiva Pty LtdNCT06964191 Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionGlaucoma, Open-Angle; Ocular Hypertensionactive not recruiting75
2026-11-04P3THPharm Corp.NCT06647745 A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THPType 2 Diabetes; Hypertensionactive not recruiting222
2026-10-30 est.P2Vincentage Pharma Co., LtdNCT07360275 A Study of VCT220 in Participants With Hypertension and Obesity or OverweightHypertensionactive not recruiting160
2026-10 est.P2Vanda Pharmaceuticals VNDANCT07090161 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionHypertension; Uncontrolled Hypertensionrecruiting240
2026-09-17P3Sarfez Pharmaceuticals, Inc.NCT07223502 A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With HypHypertension (HTN)withdrawn
2026-09-17P2Novartis Pharmaceuticals NVSNCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsHypertensionactive not recruiting396
2026-09-15P2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07835971 A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential HypertensionHypertensionactive not recruiting319
2026-08-31 est.P3Santen Pharmaceutical Co., Ltd.NCT06666855 A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaOpen Angle Glaucoma; Ocular Hypertensionactive not recruiting345
2026-07-22P2/P3Qlaris Bio, Inc.NCT07354516 Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionOAG - Open-Angle Glaucoma; OHT - Ocular Hypertensioncompleted64
2026-07-02P3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07790120 A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypeUncontrolled Hypertension; Resistant Hypertensioncompleted256
2026-06-19P3AbbVie ABBVNCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SROpen-Angle Glaucoma; Ocular Hypertensioncompleted455

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hypertension"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.